National Wealth Management Group’s Matinas BioPharma MTNB Stock Holding History

National Wealth Management Group’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-765	Closed	-$6.05K	–	161
2024 Q2	$6.05K	Sell	765 -70	-8%	-$634	﹤0.01%	130
2024 Q1	$11.3K	Hold	835	–	–	0.01%	132
2023 Q4	$9.03K	Sell	835 -20	-2%	-$226	0.01%	131
2023 Q3	$5.56K	Sell	855 -20	-2%	-$246	0.01%	124
2023 Q2	$14.5K	Buy	875 +55	+7%	+$1.28K	0.02%	127
2023 Q1	$20.4K	Hold	820	–	–	0.02%	132
2022 Q4	$20.5K	Sell	820 -100	-11%	-$3.33K	0.02%	134
2022 Q3	$29.3K	Buy	920 +38	+4%	+$1.49K	0.04%	121
2022 Q2	$34.8K	Buy	882 +240	+37%	+$9.15K	0.04%	111
2022 Q1	$25.8K	Buy	642 +164	+34%	+$6.04K	0.02%	109
2021 Q4	$24.1K	Buy	+478	New	+$25.6K	0.02%	124

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

National Wealth Management Group's MTNB Position: Q3 2024 in Review

National Wealth Management Group sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 765 shares — an estimated $6.05K sold.

National Wealth Management Group first reported a position in MTNB in Q4 2021 and held it in 11 quarters. The position peaked at $34.8K in Q2 2022. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

National Wealth Management Group reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
National Wealth Management Group sold 765 Matinas BioPharma shares in Q3 2024, an estimated $6.05K.
National Wealth Management Group first reported a position in Matinas BioPharma in Q4 2021 and held it in 11 quarters.
National Wealth Management Group's Matinas BioPharma position peaked at $34.8K in Q2 2022.
18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on National Wealth Management Group's 13F filing for Q3 2024, filed 13 Nov 2024.